Archives: Press Releases
Alivexis To Present at GTC 2025 Japan AI Day
News -
11 March, 2025 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, announces that its computation chemistry platform technology will be presented at NVIDIA’s GTC 2025 Japan AI Day to be held on March 21, 2025 JST (March 20, 2025 PDT). GTC is a global conference for cutting-edge AI and ...continuedAlivexis Raises $0.7M USD Series D in Second Close
News -
03 March, 2025 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, announces the second closing of its Series D round in the amount of 100M JPY (approximately $0.7M USD). Investor participating in the second closing is Ohara Pharmaceutical Co., Ltd. (Headquartered in Koga City, Shiga Prefecture; CEO Seiji Ohara). ...continuedPairMap: Revolutionizing Drug Discovery with Precise Energy Calculations
News -
12 February, 2025 -
Study unlocks new frontiers in drug design by introducing intermediates in energy perturbation calculations Precise calculations of binding free energy are pivotal in reducing the high costs and inefficiencies of drug discovery. A recent study presents PairMap, an innovative computational tool that introduces intermediates for complex compound transformations. This improves the accuracy of energy ...continuedAlivexis Raises $5.1M USD Series D in First Close
News -
07 January, 2025 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, announces the first closing of its Series D round in the amount of 800M JPY (approximately $5.1M USD). Investors participating in the first closing include funds managed by JIC Venture Growth Investments Co., Ltd., DBJ Capital Co., Ltd., ...continuedAlivexis announces publication of a research article on its ground-breaking ModBind™ simulation technology
News -
20 December, 2024 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, announces that a research article entitled “ModBind, a Rapid Simulation-Based Predictor of Ligand Binding and Off-Rates” by William Sinko et. al. has been published in the Journal of Chemical Information and Modeling. This article describes the methodology, validation, ...continuedAlivexis to present ModBind™ at MACNICA booth at the AI EXPO Tokyo
News -
28 October, 2024 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S.Roy Kimura, “Alivexis”), a preclinical stage technology-driven drug discovery company, will present ModBind™, our drug discovery platform at MACNICA, Inc. booth at the 5th AI EXPO Tokyo held at Makuhari Messe, Tokyo on November 20th-22nd, 2024. The AI EXPO Tokyo is the largest trade show about AI in ...continuedCathepsin C Inhibitor Proved Effective in the Treatment of Vasculitis～Expectations for a Novel Therapeutic Agent for ANCA-Associated Vasculitis～
News -
23 August, 2024 -
Alivexis, Inc. and Hokkaido University today announced the publication of a joint research article entitled “Cathepsin C inhibition reduces neutrophil serine protease activity and improves activated neutrophil-mediated disorders,” published in Nature Communications on August 22, 2024. The research, led by Assistant Professor Yuka Nishibata, Dr. Sakiko Masuda, and Professor Akihiro Ishizu of the Graduate School ...continuedMelodia Therapeutics and Alivexis Sign Exclusive License Agreement for Cathepsin C Inhibitor Program MOD-A
News -
21 June, 2024 -
Alivexis, Inc. (headquartered in Tokyo, Japan, “Alivexis”) and Melodia Therapeutics AG (headquartered in Basel, Switzerland, “Melodia”), a company established by Forty51 Ventures, announced today that they have entered into an exclusive license agreement for the worldwide development, manufacturing, and commercialization of Alivexis’ MDI-0151, a novel Cathepsin C inhibitor with best-in-class potential. MDI-0151 is an innovative ...continuedAlivexis with Astellas Pharma Inc. to Collaborate on Novel Drug Target
News -
17 June, 2024 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura) is pleased to announce that the Company has entered into a Research Collaboration Agreement with Astellas Pharma Inc. (“Astellas”) to identify small molecule compounds for a new drug target selected by Astellas, utilizing Alivexis’ drug discovery platform ModBind™ and other technologies. The collaboration aims to ...continuedJoint Research on Novel Anti-Allergic Disease Drug Candidate Published by Alivexis, Inc. and University of Yamanashi
News -
11 April, 2024 -
Alivexis, Inc., and the University of Yamanashi announce the publication of a joint research article entitled “A highly selective KIT inhibitor MOD000001 suppresses IgE-mediated mast cell activation”, published in JACI: Global, an open-access online journal from the American Association of Allergy, Asthma and Immunology (AAAAI). The research, led by Associate Professor Yuki Nakamura and ...continued